David Cassiman1, Seymour Packman2, Bruno Bembi3, Hadhami Ben Turkia4, Moeenaldeen Al-Sayed5, Manuel Schiff6, Jackie Imrie7, Paulina Mabe8, Tsutomu Takahashi9, Karl Eugen Mengel10, Roberto Giugliani11, Gerald F Cox12. 1. Metabolic Center, University of Leuven, Leuven, Belgium. 2. University of California San Francisco, San Francisco, CA, United States. 3. Academic Medical Centre Hospital of Udine, Udine, Italy. 4. La Rabta Hospital, Tunis, Tunisia. 5. King Faisal Specialist Hospital& Research Center, Riyadh, Saudi Arabia. 6. University of Paris-Diderot, APHP and INSERM U1141, Reference Center for Inborn Errors of Metabolism, Robert-Debré Hospital, Paris, France. 7. Niemann-Pick Disease Group (UK), Tyne and Wear, UK. 8. Hospital Dr. Exequiel González Cortés, Santiago, Chile. 9. Akita University School of Medicine, Akita, Japan. 10. Villa Metabolica, Center of Pediatric and Adolescents Medicine, University Medical Center, Mainz, Germany. 11. Medical Genetics Service, HCPA, Dep. Genetics, UFRGS and INAGEMP, Porto Alegre, Brazil. 12. Clinical Development, Sanofi Genzyme, Cambridge, MA, United States. Electronic address: gerald.cox@genzyme.com.
Abstract
BACKGROUND: Acid sphingomyelinase deficiency (ASMD), [Niemann-Pick Disease Types A and B (NPD A and B)], is an inherited metabolic disorder resulting from deficiency of the lysosomal enzyme acid sphingomyelinase. Accumulation of sphingomyelin in hepatocytes, reticuloendothelial cells, and in some cases neurons, results in a progressive multisystem disease that encompasses a broad clinical spectrum of neurological and visceral involvement, including: infantile neurovisceral ASMD (NPD A) that is uniformly fatal by 3years of age; chronic neurovisceral ASMD (intermediate NPD A/B; NPD B variant) that has later symptom onset and slower neurological and visceral disease progression; and chronic visceral ASMD (NPD B) that lacks neurological symptoms but has significant disease-related morbidities in multiple organ systems. The purpose of this study was to characterize disease-related morbidities and causes of death in patients with the chronic visceral and chronic neurovisceral forms of ASMD. METHODS: Data for 85 patients who had died or received liver transplant were collected by treating physicians (n=27), or abstracted from previously published case studies (n=58). Ages at symptom onset, diagnosis, and death; cause of death; organ involvement, and morbidity were analyzed. RESULTS: Common disease-related morbidities included splenomegaly (96.6%), hepatomegaly (91.4%), liver dysfunction (82.6%), and pulmonary disease (75.0%). The overall leading causes of death were respiratory failure and liver failure (27.7% each) irrespective of age. For patients with chronic neurovisceral ASMD (31.8%), progression of neurodegenerative disease was a leading cause of death along with respiratory disease (both 23.1%) and liver disease (19.2%). Patients with chronic neurovisceral disease died at younger ages than those with chronic visceral disease (median age at death 8 vs. 23.5years). CONCLUSIONS: The analysis emphasizes that treatment goals for patients with chronic visceral and chronic neurovisceral ASMD should include reducing splenomegaly and improving liver function and respiratory status, with the ultimate goal of decreasing serious morbidity and mortality.
BACKGROUND:Acid sphingomyelinase deficiency (ASMD), [Niemann-Pick Disease Types A and B (NPD A and B)], is an inherited metabolic disorder resulting from deficiency of the lysosomal enzyme acid sphingomyelinase. Accumulation of sphingomyelin in hepatocytes, reticuloendothelial cells, and in some cases neurons, results in a progressive multisystem disease that encompasses a broad clinical spectrum of neurological and visceral involvement, including: infantile neurovisceral ASMD (NPD A) that is uniformly fatal by 3years of age; chronic neurovisceral ASMD (intermediate NPD A/B; NPD B variant) that has later symptom onset and slower neurological and visceral disease progression; and chronic visceral ASMD (NPD B) that lacks neurological symptoms but has significant disease-related morbidities in multiple organ systems. The purpose of this study was to characterize disease-related morbidities and causes of death in patients with the chronic visceral and chronic neurovisceral forms of ASMD. METHODS: Data for 85 patients who had died or received liver transplant were collected by treating physicians (n=27), or abstracted from previously published case studies (n=58). Ages at symptom onset, diagnosis, and death; cause of death; organ involvement, and morbidity were analyzed. RESULTS: Common disease-related morbidities included splenomegaly (96.6%), hepatomegaly (91.4%), liver dysfunction (82.6%), and pulmonary disease (75.0%). The overall leading causes of death were respiratory failure and liver failure (27.7% each) irrespective of age. For patients with chronic neurovisceral ASMD (31.8%), progression of neurodegenerative disease was a leading cause of death along with respiratory disease (both 23.1%) and liver disease (19.2%). Patients with chronic neurovisceral disease died at younger ages than those with chronic visceral disease (median age at death 8 vs. 23.5years). CONCLUSIONS: The analysis emphasizes that treatment goals for patients with chronic visceral and chronic neurovisceral ASMD should include reducing splenomegaly and improving liver function and respiratory status, with the ultimate goal of decreasing serious morbidity and mortality.
Authors: Joanna M Poczobutt; Andrew M Mikosz; Christophe Poirier; Erica L Beatman; Karina A Serban; Fabienne Gally; Danting Cao; Alexandra L McCubbrey; Christina F Cornell; Kelly S Schweitzer; Evgeny V Berdyshev; Irina A Bronova; François Paris; Irina Petrache Journal: Am J Respir Cell Mol Biol Date: 2021-05 Impact factor: 6.914
Authors: Margaret M McGovern; Melissa P Wasserstein; Bruno Bembi; Roberto Giugliani; K Eugen Mengel; Marie T Vanier; Qi Zhang; M Judith Peterschmitt Journal: Orphanet J Rare Dis Date: 2021-05-10 Impact factor: 4.123
Authors: Margaret M McGovern; Carlo Dionisi-Vici; Roberto Giugliani; Paul Hwu; Olivier Lidove; Zoltan Lukacs; Karl Eugen Mengel; Pramod K Mistry; Edward H Schuchman; Melissa P Wasserstein Journal: Genet Med Date: 2017-04-13 Impact factor: 8.822
Authors: Sandra Torres; Elisa Balboa; Silvana Zanlungo; Carlos Enrich; Carmen Garcia-Ruiz; Jose C Fernandez-Checa Journal: Front Physiol Date: 2017-11-30 Impact factor: 4.566